PreMa: Predictive Maintenance of Solenoid Valve in Real-Time at Embedded Edge-Level

In industrial process automation, sensors (pressure, temperature, etc.), controllers, and actuators (solenoid valves, electro-mechanical relays, circuit breakers, motors, etc.) make sure that production lines are working under the pre-defined conditions. When these systems malfunction or sometimes completely fail, alerts have to be generated in real-time to make sure not only production quality is not compromised but also safety of humans and equipment is assured. In this work, we describe the construction of a smart and real-time edge-based electronic product called PreMa, which is basically a sensor for monitoring the health of a Solenoid Valve (SV). PreMa is compact, low power, easy to install, and cost effective. It has data fidelity and measurement accuracy comparable to signals captured using high end equipment. The smart solenoid sensor runs TinyML, a compact version of TensorFlow (a.k.a. TFLite) machine learning framework. While fault detection inferencing is in-situ, model training uses mobile phones to accomplish the `on-device' training. Our product evaluation shows that the sensor is able to differentiate between the distinct types of faults. These faults include: (a) Spool stuck (b) Spring failure and (c) Under voltage. Furthermore, the product provides maintenance personnel, the remaining useful life (RUL) of the SV. The RUL provides assistance to decide valve replacement or otherwise. We perform an extensive evaluation on optimizing metrics related to performance of the entire system (i.e. embedded platform and the neural network model). The proposed implementation is such that, given any electro-mechanical actuator with similar transient response to that of the SV, the system is capable of condition monitoring, hence presenting a first of its kind generic infrastructure

A Better Proof-of-Work Fork Choice Rule

We propose a modification to the fork choice rule of proof-of-work blockchains. Instead of choosing the heaviest chain, we choose the chain with the most intrinsic work. The intrinsic work of a block is roughly the number of zeroes at the front of its hash. This modification allows us to safely decrease the confirmations required, yielding a $28.5\%$ improvement in confirmation delay or, dually, safely increase the block production rate, yielding a $16.3\%$ improvement in throughput, as compared to the vanilla Bitcoin proof-of-work fork choice rule. Our modification is at the level of the proof-of-work inequality, and thus can be composed with any other methods to improve latency or throughput that have been proposed in the literature. We report the experimental findings by measuring them on a production-grade implementation of our system, whose testnet is already deployed in the wild. Lastly, we formally prove the security of our new protocol in the Bitcoin Backbone model

Purification and Characterization of a Mitogenic Lectin from Cephalosporium, a Pathogenic Fungus Causing Mycotic Keratitis

Ophthalmic mycoses caused by infectious fungi are being recognized as a serious concern since they lead to total blindness. Cephalosporium is one amongst several opportunistic fungal species implicated in ophthalmic infections leading to mycotic keratitis. A mitogenic lectin has been purified from the mycelia of fungus Cephalosporium, isolated from the corneal smears of a keratitis patient. Cephalosporium lectin (CSL) is a tetramer with subunit mass of 14 kDa, agglutinates human A, B, and O erythrocytes, and exhibits high affinity for mucin compared to fetuin and asialofetuin but does not bind to simple sugars indicating its complex sugar specificity. CSL showed strong binding to normal human peripheral blood mononuclear cells (PBMCs) to elicit mitogenic activity. The sugar specificity of the lectin and its interaction with PBMCs to exhibit mitogenic effect indicate its possible role in adhesion and infection process of Cephalosporium

Melioidosis presenting with mediastinal lymphadenopathy masquerading as malignancy: a case report

<p>Abstract</p> <p>Introduction</p> <p>Melioidosis, endemic in Thailand and in the Northern Territory of Australia is an emerging infectious disease in India which can present with varied forms. A case of melioidosis, presenting as a rare anterior mediastinal mass which can masquerade as malignancy or tuberculosis, is described here. With treatment, our patient initially showed an increase in the size of mediastinal node and development of new submandibular node.. To the best of our knowledge, this phenomenon has not been documented in the literature and the same is highlighted in this case report. </p> <p>Case Presentation</p> <p>A 43-year-old Asian man with diabetes presented with fever, loss of appetite, weight loss for one month and painful swelling below his left mandible for five days. An examination revealed an enlarged left submandibular lymph node and bilateral axillary lymph nodes. A chest X-ray showed mediastinal widening. Computed tomography of his thorax showed a lobulated heterogeneously enhancing anterior mediastinal mass encasing the superior vena cava suggestive of malignancy. An excision biopsy of the lymph node showed granulomas suggestive of tuberculosis but bone marrow culture and lymph node aspirate culture grew <it>Burkholderia pseudomallei</it>. He was treated with parenteral ceftazidime and amoxicillin-clavulanic acid. During the course of treatment, he developed an enlargement of the submandibular lymph node on the opposite side. It gradually subsided with the continuation of therapy orally with a combination of cotrimoxazole and doxycycline for six months. A repeat computed tomography chest scan showed resolution of the mediastinal mass.</p> <p>Conclusion</p> <p>Melioidosis can present as a mediastinal mass that mimics tuberculosis or malignancy. During the initial phase of treatment of melioidosis, the appearance of new lymph nodes or an increase in the size of the existing lymph nodes does not mean treatment failure. Inexperienced clinicians may consider this as treatment failure and may switch treatment. To the best of our knowledge, this is the first report documenting this phenomenon in melioidosis cases.</p

Redefining the polypill: pros and cons in cardiovascular precision medicine

Polypill is a multi-drug formulation in a single pill intended to simplify the drug regimen and reduce medication-induced adverse effects. The most common multidrug combinations in a polypill are used to treat cardiovascular diseases and are targeted against key modifiable risk factors such as hypertension and hyperlipidemia. These contain blood-pressure lowering agents, statins, and anti-platelet agents usually in a fixed dose. Polypills can be an affordable therapeutic intervention for treating high-risk patients, as these are proven to increase patients’ adherence to medication and improve clinical outcomes. Over the previous years, randomized clinical trials of several polypills have yielded contradictory findings, raising skepticism regarding their widespread use in primary disease prevention. Here, we have reviewed the concept of polypills, the evidence-based strengths, the limitations of this polypharmacy intervention strategy, and discussed future directions for their use in the primary and secondary preventive management of cardiovascular diseases and associated risk factors

Rhizoctonia bataticola lectin (RBL) induces caspase-8-mediated apoptosis in human T-cell leukemia cell lines but not in normal CD3 and CD34 positive cells.

We have previously demonstrated immunostimulatory activity of a fungal lectin, Rhizoctonia bataticola lectin (RBL), towards normal human peripheral blood mononuclear cells. The present study aimed to explore the anticancer activities of RBL using human leukemic T-cell lines, Molt-4, Jurkat and HuT-78. RBL exhibited significant binding (>90%) to the cell membrane that was effectively inhibited by complex glycoproteins such as mucin (97% inhibition) and asialofetuin (94% inhibition) but not simple sugars such as N-acetyl-D-galactosamine, glucose and sucrose. RBL induced a dose and time dependent inhibition of proliferation and induced cytotoxicity in the cell lines. The percentage of apoptotic cells, as determined by hypodiploidy, was 33% and 42% in Molt-4 and Jurkat cells, respectively, compared to 3.11% and 2.92% in controls. This effect was associated with a concomitant decrease in the G0/G1 population. Though initiator caspase-8 and -9 were activated upon exposure to RBL, inhibition of caspase-8 but not caspase-9 rescued cells from RBL-induced apoptosis. Mechanistic studies revealed that RBL induced cleavage of Bid, loss of mitochondrial membrane potential and activation of caspase-3. The expression of the anti-apoptotic proteins Bcl-2 and Bcl-X was down regulated without altering the expression of pro-apoptotic proteins--Bad and Bax. In contrast to leukemic cells, RBL did not induce apoptosis in normal PBMC, isolated CD3+ve cells and undifferentiated CD34+ve hematopoietic stem and progenitor cells (HSPCs). The findings highlight the differential effects of RBL on transformed and normal hematopoietic cells and suggest that RBL may be explored for therapeutic applications in leukemia

Effect of RBL on different phases of cell cycle.

<p>(A) Molt -4 and Jurkat cells, treated with RBL, were stained with PI and acquired on FL2-A channel of flow cytometer equipped with 488nm laser. The X-axis represents the DNA content of the cells and the Y-axis represents the cell number. The graph depicts the percentage of Molt-4 (B) and Jurkat (C) cells in different phases of cell cycle. The data is mean ±SE of three independent experiments. *p<0.05 significant difference between untreated and RBL treated cells.</p